
Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Doximity reports after the close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-08-06 | -$0.97 (-4.48%) | $2.55 (11.81%) | +$6.74 (+32.62%) | $12.84 (62.15%) |
| 2026-05-13 | -$3.06 (-11.57%) | $3.28 (12.40%) | -$5.38 (-23.00%) | $1.25 (5.34%) |
| 2026-02-05 | -$1.93 (-5.48%) | $3.17 (8.99%) | -$5.59 (-16.78%) | $4.23 (12.70%) |
| 2025-11-06 | -$1.41 (-2.20%) | $2.28 (3.56%) | -$8.29 (-13.25%) | $4.89 (7.81%) |
| 2025-08-07 | +$0.42 (+0.72%) | $1.74 (2.99%) | +$8.03 (+13.71%) | $6.68 (11.41%) |
| 2025-05-15 | -$1.05 (-1.76%) | $2.47 (4.15%) | -$5.89 (-10.08%) | $4.93 (8.43%) |
| 2025-02-06 | +$0.12 (+0.21%) | $1.73 (2.97%) | +$20.97 (+35.99%) | $9.21 (15.81%) |
| 2024-11-07 | +$1.07 (+2.53%) | $1.38 (3.26%) | +$14.83 (+34.15%) | $5.65 (13.01%) |
| Avg Abs Move | 3.62% | 6.27% | 22.45% | 17.08% |
Doximity's post-earnings price action has been exceptionally volatile, with an average absolute Day +1 move of 22.45%—far exceeding the typical software stock. The most recent quarter (August 2026) exemplifies this pattern: the stock surged 32.62% the day after results, driven by a revenue beat and optimism around AI tool adoption, despite an EPS miss. This followed a brutal 23.00% decline in May 2026 after disappointing guidance.
Historically, the direction of the move has been mixed but often dramatic. February 2025 saw a 35.99% Day +1 gain, and November 2024 delivered a 34.15% surge, both following strong results and upbeat commentary. Conversely, the stock has experienced sharp selloffs when guidance disappoints, as seen in the May and February 2026 reports.
The Day 0 moves are more muted, averaging 3.62%, suggesting most of the reaction occurs once investors digest the full earnings details and management commentary. Investors should prepare for significant volatility: the historical range suggests a move of 20% or more is entirely plausible, with the direction hinging on whether Doximity can demonstrate progress on AI monetization and stabilize pharma advertising trends.
| Metric | Value |
|---|---|
| Expiration Date | 11/20/26 (DTE 16) |
| Expected Move | $6.21 (17.90%) |
| Expected Range | $28.47 to $40.88 |
| Implied Volatility | 124.42% |
The options market is pricing a 17.90% expected move by the November 20 expiration, implying a range of roughly $28.47 to $40.88. This is notably lower than Doximity's historical average Day +1 move of 22.45%, suggesting options may be underpricing the potential for volatility. Given the stock's track record of 30%+ swings following earnings—particularly when AI or guidance commentary surprises—traders positioning for outsized moves may find asymmetric opportunities in the options market.
Analysts remain cautious on Doximity, with a consensus rating of 3.39 out of 5.00—squarely in Hold territory. The breakdown shows 4 Strong Buys, 4 Moderate Buys, 13 Holds, 1 Moderate Sell, and 1 Strong Sell across 23 analysts. This distribution reflects divided opinion: bulls see AI-driven upside and a sticky physician network, while bears worry about execution risk and margin pressure.
The average price target sits at $30.95, implying modest downside from the current price of $34.67. However, the range is wide: the high estimate of $47.00 suggests some analysts see significant upside if AI monetization accelerates, while the low of $18.00 reflects deep skepticism about the company's ability to reignite growth.
Sentiment has been unchanged over the past month, with the rating distribution holding steady at 3.39. This stability suggests analysts are in wait-and-see mode heading into earnings, with estimates largely reconfirmed rather than revised. The lack of recent upgrades or downgrades indicates the Street is looking for this release to provide clarity on whether Doximity's AI investments are translating into tangible revenue growth and margin improvement.
Doximity's technical setup heading into earnings is exceptionally strong. The Barchart Technical Opinion currently stands at 100% Buy, up sharply from 88% Buy a week ago and 56% Buy a month ago. This rapid strengthening reflects powerful momentum as the stock has rallied into the release.
Timeframe Analysis:
The trend is characterized by Average strength but ranks in the Top 1% for direction, meaning the stock is outperforming nearly all peers in terms of directional momentum, even if the underlying trend strength is moderate. This combination suggests the rally is broad-based but may be vulnerable to a sharp reversal if earnings disappoint.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $33.31 | 50-Day MA | $28.79 |
| 10-Day MA | $33.42 | 100-Day MA | $25.58 |
| 20-Day MA | $32.30 | 200-Day MA | $25.43 |
The stock is trading above all key moving averages, with the current price of $34.67 well above the 5-day ($33.31), 10-day ($33.42), 20-day ($32.30), 50-day ($28.79), 100-day ($25.58), and 200-day ($25.43) averages. This alignment indicates a strong uptrend across all timeframes, with no overhead resistance from moving averages.
The setup is supportive from a momentum perspective, but the sharp rally into earnings raises the stakes: the stock has priced in optimism, and any disappointment on AI traction, guidance, or margins could trigger a swift reversal. Conversely, a beat-and-raise scenario could extend the breakout, given the technical strength and lack of nearby resistance.